Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SystImmune to Receive $250M BMS Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

SystImmune to Receive $250M BMS Milestone

Initiates global Phase 2/3 study of izalontamab brengitecan (iza-bren) in triple negative breast cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
SystImmune

SystImmune, Inc., a clinical-stage biotechnology company, has dosed the first patient in the IZABRIGHT-Breast01 study, a global Phase 2/3 registrational study of izalontamab brengitecan (iza-bren) in triple negative breast cancer. This milestone triggers a one-time payment of $250 million by Bristol Myers Squibb, under the companies collaboration and license agreement. 

SystImmune is eligible to receive up to an additional $250 million in contingent near-term payments and additional payments of up to $7.1 billion contingent upon the achievement of certain development, regulatory and sales performance milestones.

Iza-bren is a potential first-in-class bispecific topoisomerase 1 inhibitor-based antibody-drug conjugate (ADC) that targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It is being developed by SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. in China and jointly developed by SystImmune and BMS in territories outside of China.

“Together with Bristol Myers Squibb, we have made significant progress in developing iza-bren globally. We remain deeply committed to delivering this potentially transformative therapy to patients with triple negative breast cancer and other solid tumors,” said Dr. Jie D’Elia, CEO, SystImmune. “This $250 million milestone not only reflects the progress of our collaboration but also significantly reinforces our financial position, enabling us to accelerate the global development of our differentiated ADC portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics